Clinical Trials
13 trialsNCT04984837 2026-04-20
Study of Lacutamab in Peripheral T-cell Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Recruiting
NCT03259503 2025-11-10
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03496779 2025-07-30
Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT01701986 2025-02-28
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03703375 2024-07-08
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
Celgene
Phase 3 Active not recruiting
NCT04220008 2024-01-12
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05821192 2023-04-20
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
The First Hospital of Jilin University
Phase NA Unknown
NCT01746173 2023-01-30
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT05466318 2022-07-25
ChiCGB vs BEAM in High-risk or R/R Lymphomas
Sichuan University
Phase 3 Unknown
NCT00481871 2020-01-07
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Acrotech Biopharma Inc.
Phase 1/2 Completed
NCT01822886 2019-10-14
FIL_GEMRO
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
NCT01719835 2018-03-15
CHEMO-T
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT02961816 2017-04-21
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn